Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell carcinoma patients

Dr Sophie Merrick - University College London, London, UK
Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell carcinoma patients ( Dr Sophie Merrick - University College London, London, UK )
17 Mar 2026

Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC

Dr Jan-Jaap Mellema - The Netherlands Cancer Institute, Amsterdam, The Netherlands
Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC ( Dr Jan-Jaap Mellema - The Netherlands Cancer Institute, Amsterdam, The Netherlands )
17 Mar 2026

Lutetium-177 PSMA-617 improves progression-free survival without worsening QoL in mHSPC

Dr Michael Morris - Memorial Sloan Kettering Cancer Center, New York, USA
Lutetium-177 PSMA-617 improves progression-free survival without worsening QoL in mHSPC ( Dr Michael Morris - Memorial Sloan Kettering Cancer Center, New York, USA )
17 Mar 2026

Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen deprivation alone

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA
Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen deprivation alone ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )
17 Mar 2026

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA
Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )
17 Mar 2026

Cabozantinib shows clinical benefit in refractory GCT with over 40% disease control

Dr Jennifer King - Indiana University School of Medicine, Indianapolis, USA
Cabozantinib shows clinical benefit in refractory GCT with over 40% disease control ( Dr Jennifer King - Indiana University School of Medicine, Indianapolis, USA )
17 Mar 2026

Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC

Prof Steffen Rausch - University of Tübingen, Tübingen, Germany
Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC ( Prof Steffen Rausch - University of Tübingen, Tübingen, Germany )
17 Mar 2026

Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows promising responses in metastatic clear cell RCC

Dr Karie Runcie - Columbia University, New York, USA
Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows promising responses in metastatic clear cell RCC ( Dr Karie Runcie - Columbia University, New York, USA )
17 Mar 2026

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
17 Mar 2026

ASCO GU 2026: Updates in localised prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ASCO GU 2026: Updates in localised prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
17 Mar 2026

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia,
Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia, )
6 Mar 2026

Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer

Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA
Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )
6 Mar 2026